Business Analysis Report Hikma Pharmaceuticals and AstraZeneca
| dc.contributor.advisor | Hawas, Amira | |
| dc.contributor.author | Almousa, Tareq | |
| dc.date.accessioned | 2024-11-06T09:47:19Z | |
| dc.date.issued | 2024 | |
| dc.description.abstract | This report presents a comprehensive business analysis of Hikma Pharmaceuticals and AstraZeneca, two prominent players in the global pharmaceutical industry. Despite differences in scale, regional market focus, and product portfolios, both companies have demonstrated resilience and growth within a competitive and rapidly evolving sector. Through a detailed examination of their financial performance, strategic initiatives, R&D investments, and market positioning, this report highlights the unique strengths, challenges, and competitive advantages of each company. It also explores how regulatory factors, innovation in drug development, and global healthcare trends impact both firms. The findings aim to provide insights into how each company adapts to external pressures, fosters innovation, and leverages strategic partnerships to enhance its market share and ensure long-term profitability. | |
| dc.format.extent | 44 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14154/73484 | |
| dc.language.iso | en | |
| dc.publisher | University of Sussex | |
| dc.subject | Business Analysis Report Hikma Pharmaceuticals and AstraZeneca | |
| dc.title | Business Analysis Report Hikma Pharmaceuticals and AstraZeneca | |
| dc.type | Thesis | |
| sdl.degree.department | University of Sussex Business School | |
| sdl.degree.discipline | Finance and Management | |
| sdl.degree.grantor | University of Sussex | |
| sdl.degree.name | Masters in Finance and Management |